Cantor Fitzgerald Begins Coverage on Apellis Pharmaceuticals (NASDAQ:APLS)
Cantor Fitzgerald began coverage on shares of Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) in a research note published on Tuesday morning, Marketbeat.com reports. The brokerage issued an overweight rating and a $44.00 price objective on the stock. Cantor Fitzgerald also issued estimates for Apellis Pharmaceuticals’ FY2025 earnings at ($0.94) EPS. APLS has been the subject […]
Cantor Fitzgerald began coverage on shares of Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) in a research note published on Tuesday morning, Marketbeat.com reports. The brokerage issued an overweight rating and a $44.00 price objective on the stock. Cantor Fitzgerald also issued estimates for Apellis Pharmaceuticals’ FY2025 earnings at ($0.94) EPS. APLS has been the subject […]
